1-[(2R,3R,4R,5S,6S)-3,5-diacetyl-4-azido-6-[(2S,3S,4R,5R,6R)-3,5-diacetyl-4-azido-3,5-dihydroxy-6-(1-hydroxy-2-oxopropyl)oxan-2-yl]sulfanyl-3,5-dihydroxyoxan-2-yl]-1-hydroxypropan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[(2R,3R,4R,5S,6S)-3,5-diacetyl-4-azido-6-[(2S,3S,4R,5R,6R)-3,5-diacetyl-4-azido-3,5-dihydroxy-6-(1-hydroxy-2-oxopropyl)oxan-2-yl]sulfanyl-3,5-dihydroxyoxan-2-yl]-1-hydroxypropan-2-one
• 化学式: C24H32N6O14S
• 分子量: 660.6
• InChiKey: WBBYSQBPGGAUDA-OXFSJLTFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  45
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  296
• 氢给体数：
  6
• 氢受体数：
  19

文献信息

• GALACTOSIDE INHIBITOR OF GALECTIN-3 AND ITS USE FOR TREATING PULMONARY FIBROSIS
  申请人：Galecto Biotech AB

  公开号：EP2914269A1

  公开（公告）日：2015-09-09
• [EN] GALACTOSIDE INHIBITOR OF GALECTIN-3 AND ITS USE FOR TREATING PULMONARY FIBROSIS<br/>[FR] GALACTOSIDE INHIBITEUR DE LA GALECTINE-3 ET SON UTILISATION POUR LE TRAITEMENT DE LA FIBROSE PULMONAIRE
  申请人：GALECTO BIOTECH AB

  公开号：WO2014067986A1

  公开（公告）日：2014-05-08

  The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.